Senti Biosciences, Inc. (SNTI) on Tuesday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to SENTI-202, its off-the-shelf CAR-NK therapy being developed for relapsed or refractory AML and other hematologic cancers.
This recognition comes from new Phase 1 data that shows the treatment can specifically target leukemic cells without harming healthy stem cells. It follows Senti's earlier Orphan Drug Designation this year.
The company presented updated SENTI-202 data at the 2025 ASH Annual Meeting, and there's an investor webcast lined up for December 9.
SNTI is currently trading at $2.6083, up $0.2183 or 9.13 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.